U.S. Clinical Trial Logistics Market to Reach $3.13 Billion by 2035 as Biologics Demand Grows
Updated
Updated · Precedence Research · Jun 5
U.S. Clinical Trial Logistics Market to Reach $3.13 Billion by 2035 as Biologics Demand Grows
3 articles · Updated · Precedence Research · Jun 5
Summary
$3.13 billion by 2035 is the new forecast for the U.S. clinical trial supply and logistics market, up from $1.54 billion in 2025 and $1.66 billion in 2026.
7.35% annual growth is being driven by more complex trials, rising use of biologics and personalized medicine, and greater need for temperature-controlled, time-sensitive delivery across decentralized trial sites.
Logistics and distribution held the largest service share in 2025, while manufacturing is projected to expand fastest as biologics, cell and gene therapies, and small-batch trial production require more specialized support.
Phase III trials dominated demand in 2025, but Phase II is expected to grow fastest; cardiovascular disease led therapeutic areas, while oncology is set for stronger expansion during the forecast period.
AI and cryogenic logistics are emerging growth levers, even as cold-chain costs, fuel prices and broader supply-chain vulnerabilities continue to constrain the market.